Adheris Health Limited · ASX:AHE
Adheris Health — Shareholder Meeting (November 2022)
43 slides from Adheris Health's shareholder meeting presentation, Nov 30, 2022
Slide 1: A global leader in digital medication adherence
A global leader in digital medication adherence 2022 Annual General Meeting 30 NOVEMBER 2022 MedAdvisor Limited ABN 17 145 327 617
Slide 2: Important notice and disclaimer
Important notice and disclaimer This Presentation is dated 30 November 2022 or have authority to give, any representations or likelihood of achievement of any forward- Securities Act). Securities may not be offered or and has been prepared by MedAdvisor Limited warranties (express or implied) as to,
Slide 3: Your Board of Directors
Your Board of Directors Linda Rick Jim Sandra Jenkinson Ratliff Xenos Hook Non-Executive CEO & Managing Non-Executive Non-Executive Chair Director Director Director Anthony RaeAnn Lucas Kevin Tassone Grossman Merrow Hutchinson Non-Executive Non-Executive Non-Executive Non-Executive Director Director
Slide 4: AGM agenda
AGM agenda Chair address CEO address Resolutions & voting Q&A MedAdvisor 2022 Annual General Meeting | 4
Slide 5: How to cast a vote online
How to cast a vote online 1 1 When the poll is open, select the Items of Business vote icon at the top of the screen 2A To vote, select either ‘For’, ‘Against’ 2A 2A Re-elect Mr Sam Sample as a Director or ‘Abstain’ FOR AGAINST ABSTAIN 2B You will see a vote confirmation 2B 2B Re-elect Ms Jane Citiz
Slide 6: How to ask a question
How to ask a question 1 4 1 To ask a written question select the Q & A icon 3 2 Select the topic your question relates to from the drop-down list 3 Type your question in the text box and press the send button 4 To ask a verbal question follow the 2 instructions below the broadcast window MedAdvisor
Slide 7: Chair's address
Chair’s address “ MedAdvisor has world class digital and data platforms with unparalleled patient “ reach driving marketplace economics. Linda Jenkinson MedAdvisor 2022 Annual General Meeting | 7
Slide 8: CEO's address
CEO’s address “ FY22 was a year of consolidation, progress, achievement and results. MedAdvisor remains focused on executing its global growth strategy and scaling its unique product suite “ in the US, Australia, New Zealand and the UK. Rick Ratliff MedAdvisor 2022 Annual General Meeting | 8
Slide 9: Medication adherence is a global issue
Medication adherence is a global issue “More health benefits worldwide would result from improving adherence to existing treatments than developing any new medical treatment.”1 Global cost of medication non-adherence to governments2 USA USD $290B ~50% of adults ~50% global non− Pop: 333M have a chro
Slide 10: MedAdvisor's growth journey
MedAdvisor’s growth journey 2023 - 2024 2020 - 2022 2012 - 2019 Strong foundation Market & digital expansion Pathway to profitability • 2012: MedAdvisor founded • US: Adheris Health acquisition • Rollout single global platform • 2013: Patient mobile app • UK: Development / roll out • Optimize busine
Slide 11: MedAdvisor's reach today
MedAdvisor’s reach today MedAdvisor provides digital medication adherence solutions in target markets Total network pharmacies: 37,234 Medication Adherence Platform Total network patients: 235M Enables pharmacy and patient engagement Australia US Network Pharmacies Network Pharmacies 5,000 32,023 Ne
Slide 12: Increased revenue and margin in FY22 as business scaled
Increased revenue and margin in FY22 as business scaled Group revenue ANZ revenue US revenue Group EBITDA $67.8m $14.1m $53.7m ($11.3m) +18.7% LFL 1 +44% YOY +13% LFL 1 +9.9% LFL 1 Group operating cash Group gross margin ANZ gross margin US gross margin flow $35.0m 83.3% 47.5% 2 ($0.2m) +17.3% LFL 3
Slide 13: Material business risks
Material business risks The following is a summary of the material business risks of the Company (which are not listed in order of importance or likelihood). These risks may adversely impact on the Company’s financial and operating performance and prospects. MedAdvisor reported a loss (before income
Slide 14: FY22 group achievements underpin positive start to FY23
FY22 group achievements underpin positive start to FY23 FY22 Achievements FY23 Year-to-Date Acquisition of GuildLink growing AU pharmacy network to over 5,000 locations (90% of market) GuildLink integration progressing according to plan with roll out expected to finish in June 2023 Expanded pharmacy
Slide 15: MedAdvisor's growth journey
MedAdvisor’s growth journey 2023 - 2024 2020 - 2022 2012 - 2019 Strong foundation Market & digital expansion Pathway to profitability • 2012: MedAdvisor founded • US: Adheris Health acquisition • Rollout single global platform • 2013: Patient mobile app • UK: Development / roll out • Optimize busine
Slide 16: Pathway to profitability
Pathway to profitability Our focus in FY23 is on initiatives that will move the MedAdvisor business towards breakeven as we lay the foundation for profitability in FY24 Global Platform Business Operations Product Innovation Deploy our next gen global Execute regional / global Establish MedAdvisor as
Slide 17: Delivering efficiencies from next gen global platform
Delivering efficiencies from next gen global platform We will deploy our next generation global medication adherence platform designed to be a single cross-regional platform – facilitating regional expansion at reduced cost. Modern A single core Automation built- Cloud-first technology built system
Slide 18: Delivering efficiencies from business operations
Delivering efficiencies from business operations Initiative Description Status 11 US Restructuring Phase 1 • Reduction in headcount across all US operations reducing Complete headcount by 15% 22 US Restructuring Phase 2 • Optimize team structure to support investment in sales, Early account manageme
Slide 19: UK growth opportunity reinforced
UK growth opportunity reinforced… Like AU, US and NZ, community pharmacies can be supported with patient engagement by Strategic alignment simplifying their processes to manage medications Sizeable market Two-thirds of the UK pharmacy market (7,500 pharmacies) could benefit from opportunity MedAdvis
Slide 20: Product innovation
Product innovation We are investing in development of a product innovation capability to strengthen our core products while planning for future growth. Core 85% 10% Adjacent 5% Transformational Enhancements of existing Expansion into “new to Breakthroughs and innovation to products for existing cust
Slide 21: Summary
Summary Laying the foundation in FY23 for profitability in FY24 Australia US Completing GuildLink Growing digital, integration to drive expanding sales team, further scale and and diversifying efficiencies customers NZ UK Completing rollout into Expanded roll out of the Green Cross Health MedAdvisor
Slide 22: Voting
Voting Notice of meeting and voting Notice of meeting released on 28 October 2022 and is available at www.mymedadvisor.com/investors MedAdvisor 2022 Annual General Meeting | 22
Slide 23: Annual Accounts
Annual Accounts The Annual Report including the Financial Statements for the year ended 30 June 2022 and the Reports of the Directors and Auditors thereon is tabled for consideration by members. Members should note that the Financial Statements and Reports are not tabled for approval but simply disc
Slide 24: Resolutions
Resolutions MedAdvisor 2022 Annual General Meeting | 24
Slide 25: Resolution 1: Adoption of remuneration report
Resolution 1 Adoption of remuneration report That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, approval is given for the adoption of the remuneration report as contained in the Company’s annual report for the financial year ended 30 June 2022. Please note
Slide 26: Resolution 2: Re-election of Director Jim Xenos
Resolution 2 Re-election of Director – Mr Jim Xenos That, for the purpose of clause 14.2 of the Constitution, ASX Listing Rule 14.4 and for all other purposes, Mr Jim Xenos, a Director, retires by rotation, and being eligible, is re-elected as a Director. Please note that the Voting Exclusion for th
Slide 27: Resolution 3: Re-election of Director Linda Jenkinson
Resolution 3 Re-election of Director – Ms Linda Jenkinson That, for the purpose of clause 14.4 of the Constitution, ASX Listing Rule 14.4 and for all other purposes, Ms Linda Jenkinson, who was appointed as a Director on 28 February 2022, retires, and being eligible, is re-elected as a Director. Ple
Slide 28: Resolution 4: Re-election of Director RaeAnn Grossman
Resolution 4 Re-election of Director – Ms RaeAnn Grossman That, for the purpose of clause 14.4 of the Constitution, ASX Listing Rule 14.4 and for all other purposes, Ms RaeAnn Grossman, who was appointed as a Director on 1 February 2022, retires, and being eligible, is re-elected as a Director. Plea
Slide 29: Resolution 5: Re-election of Director Anthony Tassone
Resolution 5 Re-election of Director – Mr Anthony Tassone That, for the purpose of clause 14.4 of the Constitution, ASX Listing Rule 14.4 and for all other purposes, Mr Anthony Tassone, who was appointed as a Director on 27 July 2022, retires, and being eligible, is re-elected as a Director. Please
Slide 30: Resolution 6: Re-election of Director Kevin Hutchinson
Resolution 6 Re-election of Director – Mr Kevin Hutchinson That, for the purpose of clause 14.4 of the Constitution, ASX Listing Rule 14.4 and for all other purposes, Mr Kevin Hutchinson, who was appointed as a Director on 23 November 2022, retires, and being eligible, is re-elected as a Director. P
Slide 31: Resolution 7: Approval of 10% placement capacity
Resolution 7 Special Resolution – Approval of 10% placement capacity That, for the purposes of ASX Listing Rule 7.1A and for all other purposes, approval is given for the issue of Equity Securities totalling up to 10% of the issued capital of the Company at the time of issue, calculated in accordanc
Slide 32: Resolution 8: Ratification of prior placement
Resolution 8 Ratification of prior placement under Listing Rule 7.1 That, pursuant to and in accordance with Listing Rule 7.4 and for all other purposes, Shareholders ratify the prior issue of 57,118,490 Shares at an issue price of $0.16 per Share, on the terms and conditions in the Explanatory Stat
Slide 33: Resolution 9A: Issue of options to Linda Jenkinson
Resolution 9A Issue of options to Ms Linda Jenkinson That, for the purposes of ASX Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue to Ms Linda Jenkinson, 5,000,000 options on or before 31 December 2031 (Jenkinson Options) on the terms and conditions set out
Slide 34: Resolution 9B: Issue of options to Sandra Hook
Resolution 9B Issue of options to Ms Sandra Hook That, for the purposes of ASX Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue to Ms Sandra Hook, 2,000,000 options on or before 31 December 2031 (Hook Options) on the terms and conditions set out in the Explan
Slide 35: Resolution 9C: Issue of options to Kevin Hutchinson
Resolution 9C Issue of options to Mr Kevin Hutchinson That, for the purposes of ASX Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue to Mr Kevin Hutchinson, 2,000,000 options on or before 31 December 2031 (Hutchinson Options) on the terms and conditions set o
Slide 36: Resolution 9D: Issue of options to Lucas Merrow
Resolution 9D Issue of options to Mr Lucas Merrow That, for the purposes of ASX Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue to Mr Lucas Merrow, 1,250,000 options on or before 31 December 2031 (Merrow Options) on the terms and conditions set out in the Ex
Slide 37: Resolution 9E: Issue of options to Jim Xenos
Resolution 9E Issue of options to Mr Jim Xenos That, for the purposes of ASX Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue to Mr Jim Xenos, 500,000 options on or before 31 December 2031 (Xenos Options) on the terms and conditions set out in the Explanatory
Slide 38: Resolution 10: Employee incentive options to CEO
Resolution 10 Issue of employee incentive options to Mr Richard Ratliff, CEO and Managing Director That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, approval is given for the issue of: (a) 13,327,647 options exercisable at $0.14 on or before 17 July 2029 (Initial Options);
Slide 39: Resolution 11: Increase of Non-Executive Directors' Remuneration
Resolution 11 Increase of Non-Executive Directors’ Remuneration That, for the purposes of clause 14.8 of the Constitution, ASX Listing Rule 10.17 and for all other purposes, Shareholders approve an increase of the maximum total aggregate amount of fees payable to non-executive Directors from $350,00
Slide 40: Resolution 12: Amendment to Constitution
Resolution 12 Special Resolution - Amendment to Constitution That, for the purposes of section 136(2) of the Corporations Act and for all other purposes, the constitution of the Company be modified by making the amendments contained in the document tabled at this meeting and signed by the Chair for
Slide 41: Poll
Poll MedAdvisor 2022 Annual General Meeting | 41
Slide 42: Q&A
Q&A MedAdvisor 2022 Annual General Meeting | 42
Slide 43: Your Health in Your Hands
Your Health in Your Hands ©MedAdvisor Limited ABN 17 145 327 617